Anti-MLXIPL / CHREBP Antibody (aa800-852) IHC-plusâ¢
| Name | Anti-MLXIPL / CHREBP Antibody (aa800-852) IHC-plus⢠|
|---|---|
| Supplier | LifeSpan Bioscience |
| Catalog | LS-B171 |
| Prices | $395.00 |
| Sizes | 50 µl |
| Host | Rabbit |
| Clonality | Polyclonal |
| Applications | IHC-P WB |
| Species Reactivities | Human, Bovine, Guinea Pig, Pig |
| Antigen | MLXIPL / CHREBP antibody was raised against an C-terminal synthetic peptide made to the human ChREBP protein sequence (between residues 800-852). [NCBI# NP_116569.1, isoform 1/alpha] |
| Purity/Format | Immunoaffinity purified |
| Description | Rabbit Polyclonal |
| Gene | MLXIPL |
| Conjugate | Unconjugated. Also available conjugated with Biotin , DY650 , DY488 , DY550 . |
| Supplier Page | Shop |
Product images
Anti-MLXIPL / CHREBP antibody IHC of human thymus. Immunohistochemistry of formalin-fixed, paraffin-embedded tissue after heat-induced antigen retrieval. Antibody LS-B171 concentration 5 ug/ml.
Product References
Regulation of rat hepatic L-pyruvate kinase promoter composition and activity by - Regulation of rat hepatic L-pyruvate kinase promoter composition and activity by
Xu J, Christian B, Jump DB. J Biol Chem. 2006 Jul 7;281(27):18351-62. Epub 2006 Apr 27.
Regulation of hepatic fatty acid elongase and desaturase expression in diabetes - Regulation of hepatic fatty acid elongase and desaturase expression in diabetes
Wang Y, Botolin D, Xu J, Christian B, Mitchell E, Jayaprakasam B, Nair MG, Peters JM, Busik JV, Olson LK, Jump DB. J Lipid Res. 2006 Sep;47(9):2028-41. Epub 2006 Jun 21.
Prenatal exposure to a low-protein diet programs disordered regulation of lipid - Prenatal exposure to a low-protein diet programs disordered regulation of lipid
Erhuma A, Salter AM, Sculley DV, Langley-Evans SC, Bennett AJ. Am J Physiol Endocrinol Metab. 2007 Jun;292(6):E1702-14. Epub 2007 Feb 13.
The presence of distal and proximal promoters for rat mitochondrial - The presence of distal and proximal promoters for rat mitochondrial
Aneja KK, Guha P, Shilpi RY, Chakraborty S, Schramm LM, Haldar D. Arch Biochem Biophys. 2008 Feb 1;470(1):35-43. Epub 2007 Nov 4.
Elevated hepatic fatty acid elongase-5 activity affects multiple pathways - Elevated hepatic fatty acid elongase-5 activity affects multiple pathways
Wang Y, Torres-Gonzalez M, Tripathy S, Botolin D, Christian B, Jump DB. J Lipid Res. 2008 Jul;49(7):1538-52.
Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. - Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice.
Moon YA, Hammer RE, Horton JD. J Lipid Res. 2009 Mar;50(3):412-23.
Renal mass reduction results in accumulation of lipids and dysregulation of lipid - Renal mass reduction results in accumulation of lipids and dysregulation of lipid
Kim HJ, Moradi H, Yuan J, Norris K, Vaziri ND. Am J Physiol Renal Physiol. 2009 Jun;296(6):F1297-306. doi:
Suppression of long chain acyl-CoA synthetase 3 decreases hepatic de novo fatty - Suppression of long chain acyl-CoA synthetase 3 decreases hepatic de novo fatty
Bu SY, Mashek MT, Mashek DG. J Biol Chem. 2009 Oct 30;284(44):30474-83.
The glucose-responsive transcription factor ChREBP contributes to - The glucose-responsive transcription factor ChREBP contributes to
Tong X, Zhao F, Mancuso A, Gruber JJ, Thompson CB. Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21660-5. doi:
c-Myc is required for the CHREBP-dependent activation of glucose-responsive - c-Myc is required for the CHREBP-dependent activation of glucose-responsive
Zhang P, Metukuri MR, Bindom SM, Prochownik EV, O'Doherty RM, Scott DK. Mol Endocrinol. 2010 Jun;24(6):1274-86.